CHF1535 not checked
Chiesi Farmaceutici S.p.A. · Foster 200/6 pMDI
FollowEvery change as it happens, and a Monday email
Trials
1 active
10 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Beclometasone dipropionate, formoterol fumarate (BDP/FF-200/6 µg) administered via pressurised metered-dose inhaler (pMDI) 2 inhalations bid (i.e. 2 inhalations in the morning and 2 inhalations in the evening) for a total of 12 months.”In the company’s words, NCT07666490 on ClinicalTrials.gov
- Tested for
- Asthma
- Main trialPhase 4
- “This study will evaluate the effect of triple ICS/LAMA/LABA therapy with a BDP/FF/GB 100/6/12.5 µg on asthma control outcomes relative to ICS/LABA therapy with BDP/FF 200/6 μg in a population with asthma poorly controlled.”In the company’s words, NCT07666490 on ClinicalTrials.gov
- Other names
- Foster · Fostair · Foster 200/6 pMDI
- Copy of
- Symbicort (Astrazeneca)Tested side by side with the original in NCT03888131
Other drugs for Asthma
- BenralizumabAstraZeneca · Phase 3
- HFA-152aGSK · Phase 3
- MM09Inmunotek S.L. · Phase 3
- TEV-56248Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3
- FF/UMEC/VIGSK · Phase 3
- 6103SBio · Phase 3
Coming up1
- 13 Jun 2028Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 13 Jun 2028 | BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) | |
| Phase 4Completed | 24 Feb 2023 | CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD | |
| Phase 3Completed | Mar 2012 | BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate) | |
| Phase 3Completed | 29 Nov 2012 | Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients | |
| Phase 3Completed | 17 May 2018 | TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA | |
| Phase 3Completed | 28 May 2018 | TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) | |
| Phase 3Completed | 6 May 2022 | Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN) | |
| Phase 2Completed | Sep 2012 | Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD | |
| Phase 2Completed | Apr 2014 | A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients | |
| Phase 2Completed | 16 Oct 2018 | Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026